Kite Pharma, Inc. (KITE) [Rocket]

In millions, except per share items	Dec-31-16	Dec-31-15	Dec-31-14	Dec-31-13	Dec-31-12
	10-K	10-K	10-K	10-K	10-K
Revenues	22.2	17.3	0.0	0.7	0.0
Revenue growth	28.5%		-100.0%	2025.8%
Cost of goods sold	0.0	0.0	0.0	0.7	0.0
Gross profit	22.2	17.3	0.0	0.0	0.0
Gross margin	100.0%	100.0%		0.0%	0.0%
Selling, general and administrative [+]	97.4	44.8	13.6	1.3	0.8
General and administrative	97.4	44.8	13.6	1.3	0.8
Research and development	197.9	76.4	23.1	5.1	1.8
EBITDA [+]	-262.6	-99.3	-36.4	-6.4	-2.6
EBITDA growth	164.3%	173.0%	467.8%	149.2%
EBITDA margin	-1184.4%	-575.6%		-915.7%	-7810.7%
Depreciation	6.4	1.6	0.3	0.0	0.0
EBITA	-269.0	-101.0	-36.7	-6.4	-2.6
EBITA margin	-1213.3%	-584.9%		-918.1%	-7838.1%
Amortization of intangibles	4.2	3.0
EBIT [+]	-273.2	-104.0	-36.7	-6.4	-2.6
EBIT growth	162.8%	183.6%	470.4%	149.0%
EBIT margin	-1232.2%	-602.3%		-918.1%	-7838.1%
Interest expense, net [+]	-3.6	-1.8	5.9	0.0	0.0
Interest expense	0.0	0.0	6.3	0.0	0.0
Interest income	3.6	1.8	0.4	0.1	0.0
Other income (expense), net	-0.4	0.5	0.0	0.0	0.0
Pre-tax income	-270.0	-101.7	-42.6	-6.4	-2.6
Income taxes	-2.9	0.0	0.0	0.0	0.0
Tax rate	1.1%	0.0%	0.0%		0.0%
Net income	-267.1	-101.7	-43.7	-7.8	-2.6
Net margin	-1204.6%	-589.0%		-1114.4%	-7813.8%

Basic EPS [+]	($5.46)	($2.33)	($1.91)	($1.43)	($0.48)
Growth	134.3%	21.8%	34.2%	194.4%
Diluted EPS [+]	($5.46)	($2.33)	($1.91)	($1.43)	($0.48)
Growth	134.3%	21.8%	34.2%	194.4%

Shares outstanding (basic) [+]	48.9	43.6	22.8	5.5	5.3
Growth	12.2%	91.2%	317.0%	3.0%
Shares outstanding (diluted) [+]	48.9	43.6	22.8	5.5	5.3
Growth	12.2%	91.2%	317.0%	3.0%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.